How will evolving future therapies and strategies change how we position the use of biologics in moderate to severely active inflammatory bowel disease
Parambir S. Dulai, Siddharth Singh, Niels V. Casteele, Brigid S. Boland, William J. Sandborn*
Dive into the research topics of 'How will evolving future therapies and strategies change how we position the use of biologics in moderate to severely active inflammatory bowel disease'. Together they form a unique fingerprint.